Axsome Therapeutics Inc (AXSM) Can’t Burn Your Long Portfolio. Has Another Strong Session

September 17, 2017 - By Hazel Jackson

The stock of Axsome Therapeutics Inc (NASDAQ:AXSM) is a huge mover today! The stock increased 4.21% or $0.2 on September 15, reaching $4.95. About 104,839 shares traded. Axsome Therapeutics Inc (NASDAQ:AXSM) has declined 59.08% since September 17, 2016 and is downtrending. It has underperformed by 75.78% the S&P500.
The move comes after 5 months positive chart setup for the $116.87 million company. It was reported on Sep, 17 by We have $5.10 PT which if reached, will make NASDAQ:AXSM worth $3.51 million more.

Axsome Therapeutics Inc (NASDAQ:AXSM) Ratings Coverage

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. On Monday, December 14 the stock rating was initiated by Ladenburg Thalmann with “Buy”. The stock has “Buy” rating by Brean Capital on Monday, October 3. Cantor Fitzgerald initiated the stock with “Buy” rating in Tuesday, December 15 report.

More notable recent Axsome Therapeutics Inc (NASDAQ:AXSM) news were published by: which released: “Axsome Therapeutics Inc.” on November 06, 2015, also with their article: “Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s …” published on July 17, 2017, published: “Axsome Therapeutics Sweetens The Deal For Investors” on August 29, 2017. More interesting news about Axsome Therapeutics Inc (NASDAQ:AXSM) were released by: and their article: “Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference” published on February 07, 2017 as well as‘s news article titled: “Axsome Therapeutics Appoints World Leading Experts to Depression Scientific …” with publication date: March 19, 2015.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $116.87 million. The Firm is engaged in developing therapies for the management of central nervous system disorders, including pain. It currently has negative earnings. It operates in the business of developing novel therapies for the management of CNS disorders segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: